This section of the website is for UK Healthcare Professionals only. If you are not a Healthcare Professional, please click here.
This website has been commissioned by Ipsen UK and is intended for a UK audience.
Pathology of kidney cancer and renal cell carcinoma (RCC). Epidemiology of kidney cancer and RCC. Staging and prognosis of RCC. Treatment of RCC.
CBZ-UK-000340 | November 2024
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on
01753 627777.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.
